Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ENTA Enanta Pharmaceuticals, Inc. daily Stock Chart
ENTA [NASD]
Enanta Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E25.00 EPS (ttm)4.13 Insider Own0.10% Shs Outstand18.28M Perf Week13.81%
Market Cap1.89B Forward P/E- EPS next Y-0.91 Insider Trans-83.39% Shs Float14.69M Perf Month40.17%
Income86.30M PEG- EPS next Q-0.05 Inst Own86.00% Short Float19.41% Perf Quarter34.01%
Sales238.40M P/S7.91 EPS this Y302.00% Inst Trans0.45% Short Ratio10.23 Perf Half Y17.23%
Book/sh21.97 P/B4.70 EPS next Y-154.20% ROA21.50% Target Price99.50 Perf Year29.46%
Cash/sh18.92 P/C5.45 EPS next 5Y- ROE22.80% 52W Range64.08 - 127.77 Perf YTD45.63%
Dividend- P/FCF36.12 EPS past 5Y49.50% ROI17.90% 52W High-19.27% Beta1.34
Dividend %- Quick Ratio18.70 Sales past 5Y45.20% Gross Margin- 52W Low60.96% ATR4.34
Employees113 Current Ratio18.70 Sales Q/Q83.50% Oper. Margin42.70% RSI (14)80.50 Volatility5.01% 5.21%
OptionableYes Debt/Eq0.00 EPS Q/Q60.70% Profit Margin36.20% Rel Volume2.18 Prev Close97.00
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout0.00% Avg Volume278.87K Price103.15
Recom2.70 SMA2024.28% SMA5034.25% SMA20013.47% Volume608,931 Change6.34%
Dec-13-18Initiated Berenberg Hold $80
Jun-06-18Initiated ROTH Capital Buy $133
Feb-08-18Downgrade JP Morgan Overweight → Neutral
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17Reiterated RBC Capital Mkts Outperform $54 → $58
Sep-15-17Initiated RBC Capital Mkts Outperform $54
Jul-11-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated Barclays Underweight $16 → $18
Oct-23-15Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
Oct-23-15Downgrade Barclays Equal Weight → Underweight $45 → $16
Aug-07-15Reiterated Barclays Equal Weight $35 → $45
Apr-06-15Initiated Deutsche Bank Buy $42
Mar-04-15Initiated Barclays Equal Weight $35
Aug-15-14Initiated FBR Capital Outperform $52
Jun-24-14Downgrade Robert W. Baird Outperform → Neutral
Jan-28-14Initiated Robert W. Baird Outperform $41
Feb-15-19 07:35AM  Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit New Research Emphasizes Economic Growth GlobeNewswire +6.34%
Feb-10-19 11:22PM  Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-06-19 08:43PM  Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript Motley Fool
05:10PM  Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates Zacks
04:07PM  Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot Associated Press
04:01PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018 Business Wire
Jan-30-19 10:31AM  Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy? Zacks
Jan-22-19 12:09PM  Do You Like Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At This P/E Ratio? Simply Wall St.
08:00AM  Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018 Business Wire
Jan-18-19 06:16PM  Edited Transcript of ENTA earnings conference call or presentation 26-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Jan-03-19 08:00AM  Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-20-18 08:00AM  Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-15-18 11:23AM  Here is What Hedge Funds Think About Enanta Pharmaceuticals Inc (ENTA) Insider Monkey
Dec-05-18 10:28AM  Is Enanta Pharmaceuticals Incs (NASDAQ:ENTA) CEO Pay Fair? Simply Wall St.
Nov-29-18 04:48PM  Enanta Pharmaceuticals Inc (ENTA) Files 10-K for the Fiscal Year Ended on September 30, 2018 GuruFocus.com
Nov-26-18 07:34PM  Enanta Pharmaceuticals Inc (ENTA) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:16PM  Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot Associated Press
04:01PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 Business Wire
Nov-19-18 10:30AM  Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Nov-13-18 11:40AM  Enanta Announces that AbbVies MAVYRET (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis Business Wire
11:30AM  AbbVie's MAVYRET (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis PR Newswire
Nov-07-18 10:10AM  Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals (ENTA) Zacks
Oct-29-18 07:30AM  Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 Business Wire -5.95%
Oct-26-18 08:15AM  Report: Developing Opportunities within Assured Guaranty, Potbelly, Enanta Pharmaceuticals, Seagate Technology, Ctrip.com International, and CyberArk Software Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-23-18 07:30AM  Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus Business Wire
Oct-11-18 01:31PM  How Good Is Enanta Pharmaceuticals Inc (NASDAQ:ENTA), When It Comes To ROE? Simply Wall St.
Oct-05-18 11:00AM  Liver Cancers Rising - Stocks to Watch ACCESSWIRE
Sep-25-18 08:45AM  Recent Analysis Shows Enanta Pharmaceuticals, Multi-Color, Otter Tail, Franklin Resources, CubeSmart, and EnPro Industries Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Sep-05-18 07:30AM  Enanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium Business Wire
Sep-04-18 12:01AM  Edited Transcript of ENTA earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-27-18 04:01PM  Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire
Aug-13-18 06:00AM  Why Enanta Stock Is Still a Strong Buy With Huge Upside InvestorPlace -7.46%
Aug-07-18 05:35PM  Enanta Pharmaceuticals (ENTA) Q3 Earnings and Revenues Top Estimates Zacks -8.48%
04:32PM  Enanta Pharmaceuticals: Fiscal 3Q Earnings Snapshot Associated Press
04:01PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018 Business Wire
Aug-02-18 10:08AM  Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA) Zacks
Jul-16-18 07:30AM  Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018 Business Wire
Jun-27-18 10:39AM  Achieve Life Sciences' Shares Rise on Positive Clinical Data Zacks
Jun-15-18 02:39PM  2 Stable and 2 Speculative Biotech Stocks to Buy InvestorPlace
Jun-12-18 07:30AM  Enanta Pharmaceuticals Recognizes the 1st International NASH Day Business Wire -5.10%
Jun-07-18 08:10AM  Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics ACCESSWIRE
Jun-01-18 08:38AM  Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon Zacks
07:30AM  Enanta Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Presentation to be Webcast on June 12 at 9:30 A.M. GMT Business Wire
May-29-18 05:45PM  Bayer's Generic Competition, Pipeline Setback Issues Remain Zacks
08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
May-23-18 03:05PM  Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y Zacks
May-21-18 11:09AM  AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia Zacks
May-18-18 03:21PM  Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study Zacks
May-17-18 10:09AM  Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion Zacks
May-16-18 11:00AM  Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study Zacks
May-15-18 10:45AM  Roche's Actemra Gets FDA Nod for Subcutaneous Formulation Zacks
May-14-18 01:41PM  Edited Transcript of ENTA earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-11-18 05:09PM  Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat Zacks
09:42AM  Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss Zacks
05:59AM  Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up Zacks
May-10-18 12:35PM  Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses Zacks
10:41AM  Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus Zacks
10:29AM  VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters Zacks
May-08-18 04:44PM  Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot Associated Press
04:00PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2018 Business Wire
06:59AM  Calculating The Intrinsic Value Of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Simply Wall St.
May-07-18 09:12AM  ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat Zacks
Apr-24-18 09:31AM  This Small Biotech Is Building on a Surprising Success Motley Fool
07:30AM  Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2018 Business Wire
Apr-16-18 07:40AM  Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH ACCESSWIRE
Apr-12-18 02:00AM  Enanta to Present New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH at The International Liver Congress 2018 Business Wire
Apr-09-18 05:15PM  FDA Okays Label Expansion of Pacira's Exparel's, Stock Up Zacks
Apr-06-18 06:32PM  Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why Zacks
05:35PM  Novo Nordisk Obtains Licence for Sickle Cell Disease Program Zacks
Apr-05-18 08:41AM  Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session Zacks
Apr-04-18 11:15AM  Bio-Path Leukemia Combo Study Shows Positive Early Data Zacks
07:50AM  Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-03-18 03:23PM  Alkermes Sinks as FDA Refuses Depression Drug Review Zacks
Apr-02-18 10:25AM  Edge Therapeutics Loses Edge on Failure of Late-Stage Study Zacks
Mar-28-18 07:30AM  Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2018 Business Wire
Mar-22-18 10:00AM  Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead? Zacks
Mar-21-18 09:59AM  Novo Nordisk Poised on Strong Pipeline Amid Competition Zacks
Mar-16-18 09:47AM  Alexion (ALXN) Gains On Positive Date From Lead Candidate Zacks
08:42AM  ArQule (ARQL) in Focus: Stock Moves 15.6% Higher Zacks
Mar-15-18 12:03PM  Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress Zacks
10:45AM  Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y Zacks
Mar-12-18 11:25AM  Aradigm Files MAA for Bronchiectasis Candidate in the EU Zacks
08:58AM  Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump Zacks
Mar-09-18 09:22AM  Pfizer Gets FDA Panel Backing for New Indication for Xeljanz Zacks
Mar-08-18 07:24PM  Corcept Plans Korlym Label Expansion, Pipeline in Progress Zacks
06:02AM  Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing Zacks
06:01AM  Lilly, Boehringer to Expand Jardiance Heart Failure Program Zacks
Mar-06-18 10:36AM  Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink Zacks
07:30AM  Enanta Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference Business Wire
Mar-02-18 02:33PM  Pacira (PCRX) Posts Earnings in Q4, Revenues in Line Zacks
02:29PM  Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress Zacks
12:12PM  Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y Zacks
10:53AM  Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y Zacks
Feb-28-18 12:55PM  Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4 Zacks
09:29AM  Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y Zacks
09:09AM  AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues Zacks
Feb-27-18 09:53AM  Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down Zacks
08:54AM  Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4 Zacks
Feb-23-18 08:55AM  Corcept's (CORT) Earnings and Sales Meet Estimates in Q4 Zacks
Feb-19-18 10:04AM  AbbVie Presents New Data on Upadacitinib for Crohn's Disease Zacks
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gardiner Nathaniel S.Sr. VP & General CounselFeb 13Sale95.283,270311,56223,978Feb 13 09:28 PM
CARTER BRUCE L ADirectorFeb 12Option Exercise23.405,000117,0005,000Feb 13 08:50 PM
Golumbeski GeorgeDirectorFeb 12Option Exercise27.8811,228313,01211,228Feb 13 08:57 PM
Golumbeski GeorgeDirectorFeb 12Sale90.0711,2281,011,3010Feb 13 08:57 PM
CARTER BRUCE L ADirectorFeb 12Sale90.005,000450,0000Feb 13 08:50 PM
Or Yat SunSr. VP & CSOFeb 12Sale90.076,297567,173301,916Feb 13 09:11 PM
Or Yat SunSr. VP & CSOFeb 11Option Exercise13.1825,977342,402335,897Feb 13 09:11 PM
CARTER BRUCE L ADirectorFeb 11Option Exercise23.402,73463,9762,734Feb 13 08:50 PM
Golumbeski GeorgeDirectorFeb 11Option Exercise25.582,27258,1182,272Feb 13 08:57 PM
Golumbeski GeorgeDirectorFeb 11Sale90.032,272204,5520Feb 13 08:57 PM
CARTER BRUCE L ADirectorFeb 11Sale90.022,734246,1020Feb 13 08:50 PM
Or Yat SunSr. VP & CSOFeb 11Sale89.3927,6842,474,737308,213Feb 13 09:11 PM
Gardiner Nathaniel S.Sr. VP & General CounselJan 22Option Exercise34.702,00069,40017,827Jan 24 05:21 PM
Gardiner Nathaniel S.Sr. VP & General CounselDec 06Option Exercise34.702,00069,40015,827Dec 06 08:35 PM
Ocain TimSenior Vice PresidentDec 03Option Exercise32.272,00064,5408,127Dec 04 05:42 PM
Ocain TimSenior Vice PresidentOct 01Option Exercise24.9025,000622,40031,127Oct 02 04:22 PM
Gardiner Nathaniel S.Sr. VP & General CounselOct 01Option Exercise34.701,50052,05013,827Oct 02 04:20 PM
Ocain TimSenior Vice PresidentOct 01Sale83.6425,0002,090,9036,127Oct 02 04:22 PM
Adda NathalieSr. VP & Chief Medical OfficerSep 20Option Exercise43.462,955128,4244,155Sep 21 04:18 PM
Adda NathalieSr. VP & Chief Medical OfficerSep 20Sale95.324,155396,0360Sep 21 04:18 PM
Adda NathalieSr. VP & Chief Medical OfficerAug 20Option Exercise43.462,955128,4244,465Aug 21 06:02 PM
Adda NathalieSr. VP & Chief Medical OfficerAug 20Sale92.324,155383,596310Aug 21 06:02 PM
Luly Jay R.President and CEOJul 27Option Exercise11.778,49899,990601,524Jul 30 04:57 PM
Adda NathalieSr. VP & Chief Medical OfficerJul 18Option Exercise43.462,955128,4246,555Jul 19 04:35 PM
Adda NathalieSr. VP & Chief Medical OfficerJul 18Sale124.845,045629,8431,510Jul 19 04:35 PM
Luly Jay R.President and CEOJul 06Sale125.3832,0234,014,892593,026Jul 09 04:56 PM
Luly Jay R.President and CEOJul 05Sale123.812,977368,568625,049Jul 09 04:56 PM
Adda NathalieSr. VP & Chief Medical OfficerJun 18Option Exercise43.462,955128,4247,755Jun 19 05:13 PM
MELLETT PAUL JTreasurer and CFOJun 18Option Exercise1.986,96013,79980,418Jun 20 04:22 PM
Adda NathalieSr. VP & Chief Medical OfficerJun 18Sale114.854,155477,2223,600Jun 19 05:13 PM
MELLETT PAUL JTreasurer and CFOJun 11Sale120.5715,0001,808,52373,458Jun 12 05:32 PM
Luly Jay R.President and CEOMay 17Sale105.8310,9681,160,742628,026May 18 06:02 PM
Adda NathalieSr. VP & Chief Medical OfficerMay 16Option Exercise43.462,955128,4248,955May 18 05:53 PM
Luly Jay R.President and CEOMay 16Sale105.8214,0321,484,913638,994May 18 06:02 PM
Adda NathalieSr. VP & Chief Medical OfficerMay 16Sale105.254,155437,3334,800May 18 05:53 PM
Adda NathalieSr. VP & Chief Medical OfficerApr 16Option Exercise43.462,955128,42410,225Apr 18 05:34 PM
Adda NathalieSr. VP & Chief Medical OfficerApr 16Sale85.584,225361,5606,000Apr 18 05:34 PM
MELLETT PAUL JTreasurer and CFOMar 19Sale86.489,000778,33188,458Mar 20 06:39 PM
open in yahoo | open in reuters | open in google